Consensus $738.28M. Backs FY25 adjusted EBITDA view $55M-$58M. The company said, “The Company revised its full-year 2025 guidance, as initially issued on January 15, 2025 to reflect the inclusion of $12 million to $14 million of revenue related to the acquisition of Pathline, LLC.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics reports Q1 EPS 0c, consensus (1c)
- NEO Upcoming Earnings Report: What to Expect?
- NeoGenomics price target lowered to $12 from $16 at BofA
- NeoGenomics Poised for Long-Term Growth: Buy Rating Affirmed Amid Strategic Leadership and Growth Strategy
- NeoGenomics completes acquisition of Pathline